Vyepti and Infusion site swelling - a phase IV clinical study of FDA data

Summary:

Infusion site swelling is reported only by a few people who take Vyepti.

The phase IV clinical study analyzes which people take Vyepti and have Infusion site swelling. It is created by eHealthMe based on reports of 1,576 people who have side effects while taking Vyepti from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 19, 2022

1,576 people reported to have side effects when taking Vyepti.
Among them, 5 people (0.32%) have Infusion site swelling.


What is Vyepti?

Vyepti has active ingredients of eptinezumab-jjmr. eHealthMe is studying from 1,578 Vyepti users for its effectiveness, alternative drugs and more.

What is Infusion site swelling?

Infusion site swelling is found to be associated with 598 drugs and 290 conditions by eHealthMe.

Number of Vyepti and Infusion site swelling reports submitted per year:

Could Vyepti cause Infusion site swelling?

Gender of people who have Infusion site swelling when taking Vyepti *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Infusion site swelling when taking Vyepti *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common side effects people have besides Infusion site swelling *:

  1. Infusion Site Bruising: 2 people, 40.00%
  2. Headache (pain in head): 2 people, 40.00%
  3. Rashes (redness): 1 person, 20.00%
  4. Infusion Site Rash: 1 person, 20.00%
  5. Infusion Site Pain: 1 person, 20.00%

Common conditions people have *:

  1. Migraine (headache): 2 people, 40.00%
  2. Headache (pain in head): 1 person, 20.00%

* Approximation only. Some reports may have incomplete information.

Do you take Vyepti and have Infusion site swelling?

Check whether Infusion site swelling is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Infusion site swelling and when was it recovered:

Expand to all the drugs that have ingredients of eptinezumab-jjmr:

Alternative drugs to, pros and cons of Vyepti:

Common Vyepti side effects:

Browse all side effects of Vyepti:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Infusion site swelling treatments and more:

COVID vaccines that are related to Infusion site swelling:

Common drugs associated with Infusion site swelling:

All the drugs that are associated with Infusion site swelling:

Common conditions associated with Infusion site swelling:

All the conditions that are associated with Infusion site swelling:

How the study uses the data?

The study uses data from the FDA. It is based on eptinezumab-jjmr (the active ingredients of Vyepti) and Vyepti (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: